In Q1 2018, Merck & Company’s (MRK) Gardasil/Gardasil 9 anti-human papillomavirus vaccine generated revenue of $660 million compared to $532 million in Q1 2017, a ~24% rise YoY (year-over-year) and a ~4% rise sequentially.
Gardasil/Gardasil 9 reported revenue of $380 million in the US market in Q1 2018, reflecting a ~4% fall YoY. It generated revenue of $280 million in international markets in Q1 2018 compared to $134 million in Q1 2017. In the marketplace, Gardasil/Gardasil 9 competes with GlaxoSmithKline’s (GSK) Cervarix.
ProQuad/MMR-II/Varivax generated revenue of $392 million in Q1 2018 compared to $355 million in Q1 2017, a rise of ~10% YoY and a fall of 3% sequentially.
In Q1 2018, in US and international markets, ProQuad/MMR-II/Varivax reported revenues of $312 million and $80 million, respectively, compared to $298 million and $57 million, respectively, in Q1 2017, rises of ~5% and ~41%, respectively, YoY.
In Q1 2018, RotaTeq generated revenue of $193 million compared to $224 million in Q1 2017, representing a ~14% fall YoY and a 21% rise sequentially.
In Q1 2018, RotaTeq generated revenues of $151 million and $42 million, respectively, from sales in US and international markets, which reflected YoY falls of ~16% and 7%, respectively.
In Q1 2018, Pneumovax 23 reported revenue of $179 million compared to $163 million in Q1 2017, which reflected a ~10% YoY rise and a ~32% sequential fall.
Pneumovax 23 generated revenues of $112 million and $66 million, respectively, from sales in US and international markets in Q1 2018, a ~1% YoY fall and a ~35% YoY rise, respectively.
Zostavax reported revenue of $62 million in Q1 2018 compared to $154 million in Q1 2017, a fall of ~58% YoY and 46% sequentially.
In Q1 2018, Zostavax generated revenues of $16 million and $48 million from the sales in the US and international markets, respectively, compared to $109 million and $45 million, respectively, in Q1 2017.
In April, Merck announced the initiation of two Phase 3 trials with PCV-15, an investigational vaccine for the prevention of pneumococcal disease. Merck’s first Phase 3 trial with PCV-15 will evaluate the safety, tolerability, and immunogenicity of the test vaccine followed by the pneumococcal vaccine polyvalent after one year in healthy individuals aged 50 years or above. Merck’s second trial with PCV-15 will evaluate the safety, tolerability, and immunogenicity of PCV-15 followed by the pneumococcal vaccine polyvalent after eight weeks in individuals with HIV.